377 related articles for article (PubMed ID: 29845246)
21. Exosomal Transfer of lncRNA H19 Promotes Erlotinib Resistance in Non-Small Cell Lung Cancer via miR-615-3p/ATG7 Axis.
Pan R; Zhou H
Cancer Manag Res; 2020; 12():4283-4297. PubMed ID: 32606925
[TBL] [Abstract][Full Text] [Related]
22. Upregulation of LncRNA-HIT promotes migration and invasion of non-small cell lung cancer cells by association with ZEB1.
Jia X; Wang Z; Qiu L; Yang Y; Wang Y; Chen Z; Liu Z; Yu L
Cancer Med; 2016 Dec; 5(12):3555-3563. PubMed ID: 27790864
[TBL] [Abstract][Full Text] [Related]
23. Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer.
Li YY; Lam SK; Mak JC; Zheng CY; Ho JC
Lung Cancer; 2013 Sep; 81(3):354-361. PubMed ID: 23769318
[TBL] [Abstract][Full Text] [Related]
24. Long Noncoding RNA LINC00460 Promotes the Gefitinib Resistance of Nonsmall Cell Lung Cancer Through Epidermal Growth Factor Receptor by Sponging miR-769-5p.
Ma G; Zhu J; Liu F; Yang Y
DNA Cell Biol; 2019 Feb; 38(2):176-183. PubMed ID: 30601026
[TBL] [Abstract][Full Text] [Related]
25. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y
Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
[TBL] [Abstract][Full Text] [Related]
26. APE1 shRNA-loaded cancer stem cell-derived extracellular vesicles reverse Erlotinib resistance in non-small cell lung cancer via the IL-6/STAT3 signalling.
Tang CH; Qin L; Gao YC; Chen TY; Xu K; Liu T; Ren T
Clin Transl Med; 2022 May; 12(5):e876. PubMed ID: 35605028
[TBL] [Abstract][Full Text] [Related]
27. Hyperoside exhibits anticancer activity in non‑small cell lung cancer cells with T790M mutations by upregulating FoxO1 via CCAT1.
Hu Z; Zhao P; Xu H
Oncol Rep; 2020 Feb; 43(2):617-624. PubMed ID: 31894285
[TBL] [Abstract][Full Text] [Related]
28. Gambogenic acid inhibits fibroblast growth factor receptor signaling pathway in erlotinib-resistant non-small-cell lung cancer and suppresses patient-derived xenograft growth.
Xu L; Meng X; Xu N; Fu W; Tan H; Zhang L; Zhou Q; Qian J; Tu S; Li X; Lao Y; Xu H
Cell Death Dis; 2018 Feb; 9(3):262. PubMed ID: 29449529
[TBL] [Abstract][Full Text] [Related]
29. Sensitivity of non-small cell lung cancer to erlotinib is regulated by the Notch/miR-223/
Zhang H; Chen F; He Y; Yi L; Ge C; Shi X; Tang C; Wang D; Wu Y; Nian W
Biosci Rep; 2017 Jun; 37(3):. PubMed ID: 28507201
[TBL] [Abstract][Full Text] [Related]
30. LncRNA BLACAT1 is involved in chemoresistance of non‑small cell lung cancer cells by regulating autophagy.
Huang FX; Chen HJ; Zheng FX; Gao ZY; Sun PF; Peng Q; Liu Y; Deng X; Huang YH; Zhao C; Miao LJ
Int J Oncol; 2019 Jan; 54(1):339-347. PubMed ID: 30387831
[TBL] [Abstract][Full Text] [Related]
31. LncRNA H19 downregulation confers erlotinib resistance through upregulation of PKM2 and phosphorylation of AKT in EGFR-mutant lung cancers.
Chen C; Liu WR; Zhang B; Zhang LM; Li CG; Liu C; Zhang H; Huo YS; Ma YC; Tian PF; Qi Q; Li JJ; Tang Z; Zhang ZF; Giaccone G; Yue DS; Wang CL
Cancer Lett; 2020 Aug; 486():58-70. PubMed ID: 32439420
[TBL] [Abstract][Full Text] [Related]
32. Tumour-derived exosomal lncRNA-SOX2OT promotes bone metastasis of non-small cell lung cancer by targeting the miRNA-194-5p/RAC1 signalling axis in osteoclasts.
Ni J; Zhang X; Li J; Zheng Z; Zhang J; Zhao W; Liu L
Cell Death Dis; 2021 Jul; 12(7):662. PubMed ID: 34215717
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of lncRNA EGFR‑AS1 is associated with a poor prognosis and promotes chemotherapy resistance in non‑small cell lung cancer.
Xu YH; Tu JR; Zhao TT; Xie SG; Tang SB
Int J Oncol; 2019 Jan; 54(1):295-305. PubMed ID: 30431074
[TBL] [Abstract][Full Text] [Related]
34. Increased serum exosomal long non-coding RNA SNHG15 expression predicts poor prognosis in non-small cell lung cancer.
Han P; Zhao J; Gao L
J Clin Lab Anal; 2021 Nov; 35(11):e23979. PubMed ID: 34551140
[TBL] [Abstract][Full Text] [Related]
35. Exosomal lncRNA FOXD3-AS1 upregulates ELAVL1 expression and activates PI3K/Akt pathway to enhance lung cancer cell proliferation, invasion, and 5-fluorouracil resistance.
Mao G; Mu Z; Wu DA
Acta Biochim Biophys Sin (Shanghai); 2021 Nov; 53(11):1484-1494. PubMed ID: 34605863
[TBL] [Abstract][Full Text] [Related]
36. E2F1-induced ferritin heavy chain 1 pseudogene 3 (FTH1P3) accelerates non-small cell lung cancer gefitinib resistance.
Zheng G; Chen W; Li W; Ding Y; Tu P; Chen W
Biochem Biophys Res Commun; 2020 Oct; 530(4):624-631. PubMed ID: 32762943
[TBL] [Abstract][Full Text] [Related]
37. Exploration of Serum Exosomal LncRNA TBILA and AGAP2-AS1 as Promising Biomarkers for Diagnosis of Non-Small Cell Lung Cancer.
Tao Y; Tang Y; Yang Z; Wu F; Wang L; Yang L; Lei L; Jing Y; Jiang X; Jin H; Bai Y; Zhang L
Int J Biol Sci; 2020; 16(3):471-482. PubMed ID: 32015683
[TBL] [Abstract][Full Text] [Related]
38. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo.
Yu W; Lu W; Chen G; Cheng F; Su H; Chen Y; Liu M; Pang X
Br J Pharmacol; 2017 Oct; 174(20):3608-3622. PubMed ID: 28749535
[TBL] [Abstract][Full Text] [Related]
40. Posttranslational modifications of FOXO1 regulate epidermal growth factor receptor tyrosine kinase inhibitor resistance for non-small cell lung cancer cells.
Xu ZH; Shun WW; Hang JB; Gao BL; Hu JA
Tumour Biol; 2015 Jul; 36(7):5485-95. PubMed ID: 26036758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
